USV Launches Liralin Range for Diverse Group of Type 2 Diabetes Patients
USV Pvt. Ltd, a leading drug manufacturer in the diabetes & cardiology segment, has announced the launch of the Liralin Range for the treatment of type 2 diabetes in Indian patients.
USV's Liralin Range is launched in 3 SKU forms: Liralin, Liralin DP & Liralin M. Liralin M will be introduced soon.
Liralin contains Linagliptin 5 mg, whereas Liralin DP is an FDC of Linagliptin 5 mg & Dapagliflozin 10 mg. Liralin M is an FDC containing Linagliptin 5 mg & Metformin 1000 mg
Liralin DP is available at INR 19.9/- per tablet, while Liralin is priced at INR 11.9/- per tablet.
Linagliptin has multiple clinical and safety advantages, making it potentially an evergreen OAD agent as monotherapy and in combination with other agents
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)